Illustrative image – not actual.Intas Biopharmaceuticals, the biotechnology company will be investing Rs.160 crore in setting up a separate manufacturing facility for monoclonal antibodies (mAbs) at Sanand, Ahmedabad.
The company had signed an MoU with the Gujarat government during the Vibrant Gujarat Global Investors' Summit 2009 for manufacturing 5,000 ltrs of this recombinant product.
Intas has acquired 23,000 sq. mtrs of land at the Matoda village near Sanand and has begun the technical studies for the project. The commercial production at the proposed mAb facility is likely to commence by 2011.
